Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis
Authors:
Open Access
- 11 May 2017
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 7 (1) , 1-8
Abstract
The precise clinicopathologic significance of myeloid differentiation primary response gene (MYD88) L265P mutation in diffuse large B-cell lymphomas (DLBCLs) remains elusive. To investigate the frequency and clinicopathologic significance of the MYD88 L265P mutation in DLBCLs, we conducted a meta-analysis of 40 published studies on 2736 DLBCL patients. We collected relevant published research findings identified using the PubMed and Embase databases. The effect sizes of outcome parameters were calculated using a random-effects model. In this meta-analysis, the MYD88 L265P mutation in DLBCL showed a significant difference according to tumor sites. The overall incidence of the MYD88 L265P mutation in DLBCLs, excluding the central nervous system and testicular DLBCLs, was 16.5%. Notably, the MYD88 L265P mutation rates of CNS and testicular DLBCL patients were 60% and 77%, respectively. Interestingly, the MYD88 L265P mutation was more frequently detected in activated B-cell-like (ABC) or non-germinal center B-cell-like (GCB) than GCB subtype (OR = 3.414, p < 0.001). The MYD88 L265P mutation was significantly associated with old age and poor overall survival, but not with sex and clinical stage. This pooled analysis demonstrates that the MYD88 L265P mutation is significantly associated with the tumor sites and molecular subtypes in DLBCL patients.Keywords
This publication has 45 references indexed in Scilit:
- MYD88L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor OutcomeClinical Cancer Research, 2016
- Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell LymphomaAmerican Journal of Surgical Pathology, 2016
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- Allele‐specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samplesBritish Journal of Haematology, 2015
- Oncogenic Mutations and Chromosomal Aberrations in Primary Extranodal Diffuse Large B-Cell Lymphomas of the Thyroid—A Study of 21 CasesThe Journal of Clinical Endocrinology & Metabolism, 2015
- Mutational analysis of primary central nervous system lymphomaOncotarget, 2014
- MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphomaLeukemia, 2014
- CD79B and MYD88 mutations in diffuse large B-cell lymphomaHuman Pathology, 2014
- Nuclear Factor-κB Pathway–Activating Gene Aberrancies in Primary Cutaneous Large B-Cell Lymphoma, Leg TypeJournal of Investigative Dermatology, 2014
- Oncogenically active MYD88 mutations in human lymphomaNature, 2010